Ribavirin Sponsors Fend Off FDAAA Safety Labeling Changes, For Now
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA said information about ribavirin-related drug resistance may have an impact on a class of investigational hepatitis C compounds in development but agreed with Merck and Genentech that labeling changes were not warranted “at this time.”